[Surgical Management of Hereditary Colorectal Cancer Syndromes].
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: hCRC should be provided at specialised centres, including genetic counselling, and be guided by interdisciplinary tumour board discussions
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In this case, surgical strategies must be re-evaluated that consider emerging immuno-oncologic therapies, such as checkpoint inhibition in MSI-positive tumours. Surgical care for patients with hCRC should be provided at specialised centres, including genetic counselling, and be guided by interdisciplinary tumour board discussions.
Colorectal cancer (CRC) is among the most common malignancies worldwide.
APA
Breßer M, Kröplin M, et al. (2026). [Surgical Management of Hereditary Colorectal Cancer Syndromes].. Zentralblatt fur Chirurgie, 151(1), 34-39. https://doi.org/10.1055/a-2724-3658
MLA
Breßer M, et al.. "[Surgical Management of Hereditary Colorectal Cancer Syndromes].." Zentralblatt fur Chirurgie, vol. 151, no. 1, 2026, pp. 34-39.
PMID
41213597 ↗
Abstract 한글 요약
Colorectal cancer (CRC) is among the most common malignancies worldwide. Approximately 10% of all CRCs are caused by monogenic hereditary tumour syndromes, collectively referred to as hereditary colorectal cancers (hCRC). The increasing use of molecular diagnostics - such as microsatellite instability (MSI) testing - is expected to significantly raise the detection rate in the coming years. hCRC can be broadly divided into polyposis syndromes (e.g. FAP, MAP) and non-polyposis syndromes (primarily Lynch syndrome). Surgical management must be tailored to the specific syndrome, and must balance oncological safety with long-term functional outcomes. In FAP, timely prophylactic colectomy is essential, whereas in MAP, the surgical strategy depends on polyp burden and tumour location. For rare polyposis syndromes such as NTHL1-, POLE-, or POLD1-associated syndromes, evidence-based recommendations are lacking, and treatment should follow FAP/aFAP protocols. Lynch syndrome is associated with a significantly increased risk of metachronous tumours. In this case, surgical strategies must be re-evaluated that consider emerging immuno-oncologic therapies, such as checkpoint inhibition in MSI-positive tumours. Surgical care for patients with hCRC should be provided at specialised centres, including genetic counselling, and be guided by interdisciplinary tumour board discussions.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.